To provide a pulverized toner excellent in the releasing ability and cleaning ability, and an image-forming apparatus for one-component developer, and a process cartridge using the pulverized toner. The pulverized toner contains a toner base particle containing at least a binder resin, a colorant, and a releasing agent, the mass ratio of the releasing agent to the binder resin is 3.0% to 6.0%, the adhesive force among the pulverized toners at 25° C. to 55° C. is 20 g to 80 g, and the pulverized toner is used for the image-forming apparatus for one-component developer containing the cleaning unit configured to dispose an elastic blade adjacent to the surface of the image bearing member so as to clean the surface.

1. Field of the Invention
The present invention relates to a pulverized toner, an image-forming apparatus for one-component developer and a process cartridge using the pulverized toner.
2. Description of the Related Art
In an oilless pulverized toner, wax is contained in the toner base particles, so that the interface of the pulverized toner tends to be generated where the wax exist. Thus, in general the oilless pulverized toner is easily affected by heat or stress, particularly the oilless pulverized toner is easily affected by the process using heat or applying stress in one-component developing process which is characterized by compact form.
In general, the polymerization toner encapsulating wax is used to ensure the resistance against heat or stress. The polymerization toner is characterized by uniformity of the particle size, and high circularity, thus, it is easy to achieve high image quality and lower production cost. On the other hand, the polymerization toner is inferior in cleaning ability. Thus, in a case of the toner produced by the conventional pulverization process, the pressing force applied to a surface of a photoconductor by an elastic blade is not enough to block the residual toner from passing through the blade, and much larger pressing force is necessary. With regard to the means for keeping the stable cleaning effect, there is a tendency that the friction coefficient of the electrophotographic photoconductor is decreased to improve the releasing ability of the toner with respect to the surface of the photoconductor, and many methods of incorporating a lubricant in a surface layer and a protective layer of an electrophotographic photoconductor are proposed. Examples of the lubricants include a fluorine resin such as polytetrafluoroethylene; resin powders such as a substantially spherical acrylic resin, and polyethylene resin; metallic oxide powders such as silicon oxide, and aluminum oxide. The means for decreasing the friction coefficient of the photoconductor at early stage has been put into practical use; for example, a coating mechanism is placed near the contact part of an elastic blade with a photoconductor to coat a toner or a lubricant, and a lubricant layer is disposed on the surface of the photoconductor. In addition, for the combined blade material, the blade material having relatively low impact resilience is likely to be used in order that the contact part with a photoconductor suppresses the vibration generated by the frictional force between the contact part and the photoconductor thereby to prevent the change of toner blocking property, noise, and fluttering sound.
However, it has been confirmed that the toner produced by adding a releasing component in the toner base particles beforehand to improve the releasing ability when fixing is likely to have higher adhesive force. Therefore, it is difficult to discharge a residual toner, which accumulates easily, after a visible image is formed on the photoconductor in a developing unit and transferred in a transferring unit, and then the residual toner on the photoconductor is blocked at the contact part of the cleaning blade with the photoconductor.
When the toner accumulation is increased at the contact part of the cleaning blade with the photoconductor, the pressing force of the toner partly exceeds blocking force of the blade, and then the toner passes through the contact part of the cleaning blade with the photoconductor. Thus, the problem of the inferior cleaning ability is frequently occurred.
Japanese Patent Application Laid-Open (JP-A) No. 2004-109602 discloses the toner in which the relation of the adhesive stress at 25° C. and 50° C. are defined. The toner is produced by salting out/fusion bonding resin particles and colorant particles in an aqueous medium, not by the melt-kneading pulverization.
Japanese Patent Application Laid-Open (JP-A) No. 2002-169326 discloses the toner in which the relation of the amount of the external additive to the toner particle diameter, and the relation of the adhesive stress to the compressive force are defined. The oilless pulverized toner needs more amount of the external additive to coat the surface of the toner. In the definition of the relation of the change to the compressive force, the exudation of the releasing agent at high temperature and high pressure, which is the inherent problem of the oilless pulverized toner, can not be improved.
Japanese Patent Application Laid-Open (JP-A) No. 2000-3063 discloses the spherical toner having the relative high-circularity of 0.960 or more, however, the adhesive stress relative to the temperature is not defined. Thus, the exudation of the releasing agent at high temperature and high pressure, which is the inherent problem of the oilless pulverized toner, can not be improved.
Japanese Patent Application Laid-Open (JP-A) No. 11-295928 discloses the toner in which the adhesive force among toners and the softening point of the binder resin at a room temperature is defined, however, the adhesive stress relative to the temperature is not defined. Thus, the exudation of the releasing agent at high temperature and high pressure, which is the inherent problem of the oilless pulverized toner, can not be improved.


Embodiments of a driver circuit for a power stage of a class-D amplifier and a class-D amplifier are described. In one embodiment, a driver circuit for a power stage of a class-D amplifier includes serially connected transistor devices connected to a gate terminal of a power transistor of the power stage of the class-D amplifier, a voltage generator connected between a gate terminal of a first transistor device of the serially connected transistor devices and a source terminal of the power transistor, and a current multiplier connected between the gate terminal of the power transistor and one of a source terminal and a drain terminal of the first transistor device. The current multiplier is configured to produce an output current that is proportional to a current at the one of the source terminal and the drain terminal of the first transistor device.

Class-D amplifiers can be used in consumer and automotive devices to achieve good signal quality, high output power, high efficiency and long-term battery life for mobile or automotive applications. For example, class-D amplifiers can be used in personal computing devices such as mobile phones, hearing aids, and audio systems such as home theatre systems, power speakers, subwoofers, and bass amplifiers.
A class-D amplifier typically includes a driver device to generate a driving signal for power transistors in the power stage of the class-D amplifier. Conventional driver devices for power stages of class-D amplifiers generally require bootstrap capacitors or a charge pump voltage for producing a reference voltage. In addition, conventional driver devices for power stages of class-D amplifiers typically have stringent capacitance requirement for transistors in driver devices. Consequently, the component cost of a conventional driver device can be substantially high.

Driver circuit for a power stage of a class-D amplifier


An error in a demand prediction of items is reduced. A data processing apparatus for processing data on a demand for multiple items includes a model learning unit that generates a prediction model for predicting the demand for the multiple items, and a demand prediction unit that predicts the demand for the multiple items by using the prediction model. The model learning unit inputs actual data of the demand for each item to a first neural network of each item, extracts a feature quantity of each item, and combines the feature quantity of each item to generate a second neural network that is a prediction model.

Patent Literature 1 discloses "there are provided a prediction model 1 in which multiple models of a neural network are stored in advance, and a prediction model 2 in which sales performances are acquired, the sales performance in a first period is input to the neural networks of the multiple models as processing elements, the respective neutral networks learn to output data as close as possible to the sales performance in a second period after the first period, a model of the neural network from which data output as a demand predicted value in the second period is closest to the sales performance in the second period is selected from the learned neutral networks, and a latest sales performance is input to the neural network of the learned model in question to predict a demand".

Data processing apparatus and data processing method


The tire mold includes a peripheral ring split into two parts (G and D). The peripheral ring is laminated. It consists of a stack in the circumferential direction of a number of thin adjacent elements (1) made, for example, of metal sheets. The elements are of two different types: standard elements and intermediate elements, which follow on from one another circumferentially. The mold includes alignment means interacting with said intermediate elements in order to impose an orientation with respect to the radial direction on said intermediate elements. These means are, for example, grooves in which the intermediate elements are engaged.

The present invention relates to the manufacture of tires. More specifically, it relates to the molding of the tread of such tires.
U.S. Pat. No. 5,492,669 describes a type of mold in which a great many metal sheets are arranged transversely to mold the tread. It is said here that the metal sheets, that is to say the molding elements, are oriented transversely because, when looking at the tire, they run from one of its shoulders to the other.
To open and close this type of mold requires coordinated movement, in a radial direction, of all the basic elements of the laminated peripheral ring. It is possible that the successive cycles of opening and of closing the mold will, in time, cause the metal sheets to become inclined with respect to their initial orientation, especially on account of parasitic friction responsible for misalignment or slippage of the metal sheets as they move while the mold is being opened and closed. Furthermore, it may prove difficult to maintain a distribution of inter-sheet clearances which is as even as might be desired. Molding flash may therefore occur in the places where the clearance between sheets has become markedly greater than the nominal clearance. Now, the desired objective is to choose the nominal clearance, as is explained in U.S. Pat. No. 5,492,669, specifically to prevent rubber from being able to run between the sheets throughout the mold-closure travel.
The objective of the invention is to overcome this drawback in order to improve the ability of a mold of this kind to mold tires with a high-quality appearance, especially with a quality of appearance which remains constant after many molding cycles.


The defect inspection apparatus and method for determining an acceptable condition of a reticle/mask member with a pattern area to be developed on a semiconductor device includes determining a non-pattern area and designating an inspection target area within a non-pattern area. Light is scanned across the inspection target area and detected to provide representative signals. The representative signals are processed to define the status of foreign matter including size and location and further compared with predetermined values to determine the acceptability of the mask for continued production purposes.

1. Field of the Invention
The present invention relates to a defect inspection apparatus and method using the principle of scattered light capable of suitably inspecting any haze deposited on a reticle/mask or pellicle film and more particularly to selection of an inspection area and processing of detected results.
2. Description of Related Art
Conventionally, if a pattern area or pellicle film that forms a pattern of a reticle/mask used for exposure during manufacturing of, for example, a semiconductor device, has defects, such as an adhesion of foreign matters or a haze (foreign matter vapor-deposited or crystallized), the resultant manufactured semiconductor device can suffer a lowering of the production yield. Consequently, the pattern area of the reticle/mask and the pellicle film are inspected for defects by using a defect inspection apparatus.
In recent years, since the wavelength of light emitted by an exposure machine of a stepper has become shorter, the photochemical reaction has become stronger, so that even a small amount of a gas component in the environment, such as air, tends to become as a haze on the production product. Consequently, success or failure of haze detection largely affects the yield of a semiconductor device.
Accordingly, Japanese Unexamined Patent Publication No. 1995-229844 is an example of haze inspection by visually inspecting the entire surface of a reticle/mask or pellicle film with a microscope for haze inspection to provide a pattern defect apparatus with an improved S/N ratio and thereby with high sensitivity.
However, there is still a need to provide an economically improved defect inspection apparatus to address the specific characteristics of a reticle/mask.


A minefield is irradiated with coherent microwave energy at a first power level. Back radiation provides an indication of the position of the landmines. Coherent microwave radiation at a second power level high than the first is directed at the hidden mines to destroy the same. The microwave energy is produced by gyrotron oscillator.

The invention concerns a method to clear minefields and an apparatus to use it. Together with a mine-detection method this leads to an automatic mechanism for land mine clearance.
The hidden land mines are an almost world-wide problem. Their number is estimated to be more than 110 million. The minefields sown during wars are often not cleared afterwards. This fact becomes understandable when you consider that one mine costs about 10 $, but its clearance costs about 200 $ up to 1,000 $ (cf. [7], p. 21).
To solve this problem, it is necessary to develop a method that clears minefields efficiently, quickly, cheaply and reliably.
A further main problem is the great risk to health of persons clearing the minefields. Statistically, 0.1% of the mines being cleared cause an accident. In Kuwait more than 80 people clearing minefields lost their lives as reported in the press. So the clearance of an evacuated minefield from a distance is advantageous, because there is no damage to men or material. Especially the anti-tank mines and the anti-helicopter mines often sown together with anti-personnel mines are a great risk for the vehicle respectively the airplane clearing the mines.
The purpose of the invention is a civil clearance of generally-hidden landbased explosive devices, for instance land mines, especially anti-personnel mines (so called APM""s). This means a clearance rate of more than 99.6% as demanded by the UN (cf. [6], p. 25).
This method works, even if the mine is a plastic mine or contains little metal. Fully metal-enclosed mines cannot be destroyed, but can be found with this method. Even other munitions, such as ammunition can be found and cleared.
The method consists in emitting specific concentrated high-power microwave radiation onto the minefield or onto the mine""s location. To locate the hidden mines the minefield is irradiated by low-power radiation and the back-radiation is received in the microwave and/or the infrared spectrum. Then specific concentrated high-power microwave radiation is used to burn down the mine.
In order to locate the mines you can also use other well-known detecting methods, for instance as described in U.S. Pat. No. 5,592,170 and other patents (see list) or Sieber et al. [4].
This method intends to destroy mines automatically from a distance.
The wavelength of microwaves is within the cm up to the dm band, that is frequencies in the SHF and EHF- band according to DIN 40015.
A land mine consists of a cover that is often made of plastic and no longer of metal, which is why their detection is difficult. The mine consists essentially of a fuse with the detonator and the explosive charge with a lower sensitivity to impact, friction and temperature-change.
Physically, the explosive has a dielectric loss Pd when irradiated by an electromagnetic wave, depending on the frequency f, the power of the electromagnetic wave, the dielectric number ∈r of the material and the dissipation factor tan(xcex4) of the explosive. So when irradiated by electromagnetic energy, the explosive of a not completely metal-enclosed mine absorbs part of the wave""s energy (cf. FIG. 4). The dielectric power loss Pd of the mine being directly exposed to the radiation is proportional to the product of the frequency f, the dielectric number ∈r and the dissipation factor tan(xcex4) of the explosive, whereas ∈r and tan(xcex4) also depend on the temperature and on the frequency f. (For highly polar materials such as water, the variation of the dielectric number ∈r with frequency is dramatic, going from 80 at 60 Hz to 20 at 10 kHz, because permanent dipols can no more follow the rapid field change.)
At various discrete values of temperature and frequency there are quasi-resonances where the loss is locally very high. A sharpe rise in dielectric loss, usually accompanied by a rapid temperature increase, is an indication of impending breakdown. If the absorbed power is high enough, the mine will burn down. The effect depends on the dissipated power inside the mine:
1) The explosive will gas out at lower temperatures and be defused,
2) the explosive will be heated above the deflagration point and burns down, or detonates when heated above the fusion point,
3) the explosive detonates immediately because the electromagnetic effect leads to electrical breakdown of the explosive depending on it""s dielectric strength.
The deflagration points and the fusion points of most explosives (as pure substances) are between 300 F. and 720 F. (cf. [5]).
If the electric field irradiating the explosive is increased to some critical magnitude, depending on the dielectric strength of the medium, the temperature, the medium surrounding the dielectric and on other factors, the material abruptly becomes conducting, a large current flows and local destruction occurs.
This electrical breakdown leads to detonation of an explosive device which is not metal-enclosed.
A further point of the invention is the use of microwave frequencies between 3 GHz and 80 GHz, so that the dielectric loss inside the explosive is high enough and the radiation penetrates the soil deeply enough.
Especially Industrial-Scientific-Medical (ISM) frequency bands according to EN 55011 and VDE 0875 are of advantage because there is no interference with radio operators and because they can effectively be generated by gyrotron oscillators according to claim 11 (see also FIG. 1). Using the ISM-frequency band of 61 GHz up to 61.5 GHz another advantage is the relatively high absorption of the stray radiation by the air at this frequency to avoid scattered radiation (no window frequency). The frequency of radiation in the known ISM-frequency band is around 5.800 GHz; 24.125 GHz; and 61.250 GHz.
The advantages of a gyrotron device besides the coherent and bundled high-power radiation compared to a magnetron radiation at say 0.91 GHz or 2.45 GHz are:
1) Because of the shorter wavelength at the higher frequency, the microwave radiation generated by a gyrotron device can be deflected and focused by relatively small quasi-optical reflectors (see (5) and (5xe2x80x2) in FIGS. 1 to 4).
2) The absorbed power in the dielectric medium (here: the explosive in the mine) being directly exposed to the radiation increases with increasing frequency and dissipation factor which also grows with higher frequency. So, compared to 2.45 GHz the absorbed power at 61.25 GHz is about 400 times higher.
3) The higher frequency establishes a higher resolution as ground-penetrating radar.
A further possibility is the pulsed emission of microwave radiation even at a higher power level. This can be done by a gyrotron device. We suggest emitting more than one pulse on each mine.
According to claim 3 you get a frequency band which penetrates the soil deeply enough and is absorbed adequately by the explosive.
Even higher frequencies do not penetrate the ground deeply enough because of their short wavelength (i.e. the function P1 decreases with decreasing xcex).
Because microwaves in the frequency band of 3 GHz up to 80 GHz are well absorbed by dielectric substances and because gyrotrons are masers with high power output of more than 10 kW cw, and total efficiency xcex7 of more than 50%, whose coherent radiation can be deflected and focused by small quasi-optical reflectors, we suggest to clear landbased minefields by defusion or explosion of the hidden mines by high-power microwave radiation.
Especially the use of radiation at a ISM-frequency of 61.250 GHz has the advantage that the stray radiation will be well absorbed by the air (no window frequency), so the scattered radiation is low.
We suggest using a gyrotron oscillator with a permanent magnet and a water edge-cooled microwave transmission window. This equipment is easy to handle and of low volume. The invented apparatus will be provided with quasi-optical reflectors in order to reflect and focus the emitted microwave radiation according to claim 13.
Gyrotrons with kW power rating and frequencies around 30 GHz are lately used for technological applications to heat ceramics by dielectric loss in a closed cavity (cf. [1]), p. 32 or [2], p. 22). To use the maser for technical applications, you even can focus the radiation on an area of less than 0.2 square inch (cf. [8], p. 8).
Last but not least, the invention suggests to fit the microwave emitter in a vehicle or an airplane, for instance a helicopter. An electric power generator supplies the equipment with electric energy.
The electronics of the vehicle must be electromagnetically shielded against the stray radiation. In addition, the microwave equipment is shielded except for the radiation exit (see FIG. 3).

Method and apparatus to clear minefields


A multi-stage elevator car has equipment for fine positioning of the cars wherein the car thresholds are positionable at the level of the floor thresholds. The fine positioning adjusting equipment operates on the principle of a double lever and moves a car frame along a path (Δz).

The present invention relates to equipment for fine positioning a car of a multi-stage car for an elevator, wherein the thresholds of the cars are positionable at the level of the floor thresholds.
An elevator with a multi-stage car is shown in the European patent specification EP 0 870 716, consisting of a main frame in which two cars are arranged. A pantograph operating on the scissors principle centrally engages at an intermediate yoke. One end of the pantograph is pivotably connected with the lower yoke of the upper car and the other end of the pantograph is pivotably connected with the upper yoke of the lower car. Two spindle drives are provided at the upper yoke of the main frame and move the upper car up and down. In the case of upward movement of the upper car, the pantograph extends, whereby the lower car executes a downward movement. In the case of downward movement of the upper car, the pantograph contracts, whereby the lower car executes an upward movement.
A disadvantage of this known equipment resides in the fact that the pantograph engaging the intermediate yoke loads the intermediate yoke with two cars. Moreover, a comprehensive control is required for fine positioning of the cars with car movement in opposite sense.

Equipment for fine positioning of a car of a multi-stage car


Compounds according formula (I)

The present invention provides pharmaceutically active compounds that facilitate secretion of growth hormone (GH) by the anterior pituitary. Growth hormone (also known as somatotropin) acts indirectly to promote skeletal growth in children by stimulating the production of insulin like growth factor-1 from the liver. Growth hormone also stimulates the differentiation of fat cells and chondrocytes (cells that secrete collagen and proteoglycans to form cartilage). In adults, growth hormone is involved in the proper maintenance of connective and muscle tissues.
Growth hormone deficiency may be congenital or acquired. Deficiency in children causes slow skeletal growth that, if not corrected, results in permanent short stature. In older adults, deficiency of growth hormone results in frailty. Additional adult symptoms of GH deficiency may include wrinkled skin and hypoglycemia.
For veterinary application, upregulation of growth hormone is useful to treat frailty in older animals, particularly companion animals. With respect to livestock, upregulation of growth hormone increases growth and performance, even in healthy animals with normal GH levels. Improvements in feed efficiency milk yield, leanness, meat quality and fertility are of note.
Although direct administration of growth hormone may be effective in certain therapeutic applications, it is difficult in practice. Among other issues, since the half-life of growth hormone in the body is very short, direct administration leads to artificially increased levels in the concentration of circulating GH, which then rapidly drop off. Sustained release, such as by a mechanical pump, has not been optimally set to practice.
The concentration of growth hormone circulating in the body depends on the balance of numerous biochemical pathways, including opposing processes. Compared to the direct administration approach, shifting the balance of these pathways indirectly provides a safer, more reproducible method to affect GH secretion on a sustained basis. Under this approach, since the overall regulatory framework remains intact, secretion rates and circulatory concentrations for GH follow a relatively normal pattern, and adverse fluctuations in both secretion rate and circulating GH concentration are avoided. The present invention provides for therapeutic compounds, and their use, to indirectly elevate growth hormone secretion from the pituitary.
Growth hormone is released from the anterior pituitary in response to stimulation by growth hormone releasing peptide (GHRP), and growth hormone releasing hormone (GHRH), of hypothalmic origin. However, release of growth hormone via these or other mechanisms is inhibited by somatostatin, and thus the process is closely regulated.
Somatostatin (SRIF) is a cyclic peptide hormone of 14 amino acids (there is also a 28 amino acid form) having numerous endocrine functions which, like many hormones, is cleaved from a larger precursor protein. Somatostatin inhibits the pituitary secretion of growth hormone, the pancreatic secretion of glucagon and insulin, and the secretion of gastrin from the gut. Somatostatin also acts as a neurotransmitter/neuromodulator (see S. J. Hocart et al., J. Med. Chem.,41, pp. 1146-1154, 1998 for a general discussion).
The biological effects of somatostatin are apparently all inhibitory in nature, and are elicited upon binding to the surface of a target cell. The receptor is an integral membrane protein (which spans the cell membrane), and is G-protein-coupled. G-protein coupled receptors represent a major class of cell surface receptors. It is believed that upon binding of somatostatin to the receptor, the receptor undergoes a conformational change facilitating its interaction with a G-protein at the cytoplasmic face of the receptor. This facilitates binding or release of GTP/GDP at the G protein, and leads to further activation and signaling events inside the cell. In particular, somatostatin binding at its own G-protein-coupled receptor is negatively coupled to adenylyl cyclase activity, which is necessary for the production of cyclic AMP. Thus, these further signaling events directly oppose mechanisms (for example, as mediated by calcium ions or cyclic AMP) whereby GHRP and GHRH would otherwise trigger extracellular secretion of growth hormone from cytoplasmic storage granules. For a general review thereof, see The Encyclopedia of Molecular Biology, J. Kendrew, ed., Blackwell Science, Ltd. 1994, at page 387.
The effects of somatostatin on target cells are mediated by at least 5 classes of receptors (sst1-sst5). Although the receptors may have similar affinity for somatostatin, they are differentially expressed in different tissues, and so positioned, interact, directly or indirectly, with different intracellular signaling components. This tissue specificity of receptor expression accounts in large measure for the different effects of somatostatin in different target cell types. Somatostatin receptors are found, for example, in tissues of the anterior pituitary, other brain tissues, the pancreas, the lung, on lymphocytes, and on mucosa cells of the intestinal tract.
The sst2 type receptor is known to mediate inhibition of growth hormone secretion in the anterior pituitary. This receptor is also reported in 2 forms, proteins sst2A and sst2B, which result from differential splicing of the sst2 gene transcript (M. Vanetti, et al., FEBS Letters, 311, pp.290-294, 1992). The sst2 receptor is also known to mediate inhibition of gastrin and histamine secretion. Additionally, the sst2 receptor is known to mediate inhibition of glucagon release from pancreatic alpha cells.
Although numerous somatostatin agonists have been described (see for example, WO 98/44922, WO 98/45285, and WO 98/44921), the development of useful sst2-linked somatostatin antagonists has lagged behind. Recent reports of such compounds include W. R. Baumbach et al., Molecular Pharmacology, 54, pp. 864-873, 1998, and S. J. Hocart et al., J. Med. Chem., 41, pp. 1146-1154, 1998.However, such compounds are short peptides, a class of molecules not often suited for successful use as pharmaceuticals because of their typically short half life in the body.
It would be advantageous to provide antagonists of somatostatin activity, effective at the sst2 type receptor, having superior properties as pharmaceuticals, including bioavailability, stability, and the like. The present invention provides a series of antagonist compounds that specifically interfere with the binding of somatostatin to the sst subtype 2 receptors of cells in the mammalian anterior pituitary, and which have additional valuable properties.
According to the practice of the present invention, there is provided a compound according to formula (I)
Axe2x80x94Gxe2x80x94Zxe2x80x94Wxe2x80x83xe2x80x83(I)
or a pharmaceutically acceptable salt, solvates or hydrate thereof,
wherein group A is (C6-C10)aryl, (C6-C10)aryl-SO2, (C6-C10)aryl-CH2xe2x80x94, (C6-C10)arylcarbonyl, (C1-C9)heteroaryl, (C1-C9)heteroaryl-SO2xe2x80x94, (C1-C9)heteroaryl-CH2xe2x80x94; or (C1-C9)heteroarylcarbonyl;
G is:
xe2x80x83where B is (C6-C10)aryl or (C1-C9)heteroaryl, and X is CH2, SO2, or carbonyl;
xe2x80x83where X is CH2, SO2, or carbonyl; and R1 and R1xe2x80x2 are each independently selected from H, CN, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted; or
xe2x80x83wherein R2 is H, (C1-C8)alkyl, or is selected from groups A above; and E is selected from groups A above;
W is (a):
xe2x80x83wherein n is 2 to 5,
R3 is selected from H, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted;
R6 is selected from H, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted;
R4 is selected from H, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted; or is
xe2x80x83where groups R10, R11 and R11xe2x80x2 are each, independently, selected from H, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, and R10 may also be selected from (C6-C10)aryl, wherein said alkyl, phenyl or other aryl groups are optionally substituted;
R5 is H, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted, or is
xe2x80x83wherein R12 and R12 are each independently selected from H, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted; or
W is (b)
wherein
Q is selected from the group consisting of (C6-C10)aryl, (C1-C9)heteroaryl, (C3-C10)cycloalkyl, and (C3-C10)heterocycloalkyl; and
R7, R8, and R9 are each independently selected from H, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted.
In a preferred aspect of the invention, there is provided a compound wherein, independently, one or more of groups A, B, E, and Q therein comprise, a (C6-C10)aryl group, selected from phenyl and naphthyl.
In a preferred aspect of the invention, there is provided a compound wherein, independently, one or more of groups A, B, E, and Q therein comprise, a (C1-C9)heteroaryl group, selected from furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5, 6, 7, 8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, and benzoxazinyl.
In a preferred aspect of the invention, there is provided a compound wherein group Q therein is selected from
(a) a (C6-C10)aryl group, selected from phenyl and naphthyl;
(b) a (C1-C9)heteroaryl group, selected from furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5, 6, 7, 8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, and benzoxazinyl;
(c) a (C3-C10)cycloalkyl group, selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,3-cyclobutadienyl, 1,3-cyclopentadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,4-cycloheptadienyl, 1,3,5-cycloheptatrienyl, bicyclo[3.2.1]octane, bicyclo [2.2.1] heptane and the norborn-2-ene unsaturated form thereof; and
(d) a (C3-C10)heterocycloalkyl group, selected from pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, and chromanyl.
In a highly preferred embodiment of the invention, there is provided a compound wherein the Z group thereof has the stereospecificity
In further examples of this embodiment, the Z group defines an L-amino acid selected from the group consisting of L-tryptophanyl-, L-histidinyl-, L-3-methylhistidinyl-, L-phenylalaninyl-, L-diphenylalaninyl-, L-3-fluorophenylalaninyl-, L-2-fluorophenylalaninyl-, L-4-fluorophenylalaninyl-, and L-tyrosinyl-, and is most preferably L-tryptophanyl-.
In a further preferred embodiment of the invention, there is provided a compound wherein the Z group thereof has the stereospecificity
and thus the Z group defines an D-amino acid which is preferably D-tryptophanyl.
In a further highly preferred embodiment of the invention, there is provided a compound wherein the W group thereof has an absolute stereospecific configuration at the indicated position which corresponds to the that of the xcex1-carbon of L-amino acids.
It is further preferred that the W group define an L-lysine group or a (C1-C8)alkyl ester thereof, or an L-arginine group or a (C1-C8)alkyl ester thereof, most preferably an (C1-C8)alkyl ester of L-lysine. Additionally, the W group can define an L-diaminopimelic, L-canavanine, L-ornithine, L-2,4-diaminobutyric, L-5-hydroxylysine, L-epsilon-N-methyllysine, L-histidine, or L-3-methylhistidine group.
Accordingly, preferred compounds of the invention include:
6-Amino-2-[2-[(biphenyl-4-ylmethyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid methyl ester;
2-{3-(3-Fluoro-phenyl)-2-[2-(toluene-4-sulfonylamino)-acetylamino]-propionylamino}-5-guanidino-pentanoic acid methyl ester;
6-Amino-2-[2-[(biphenyl-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid methyl ester;
2-{2-[(Biphenyl-4-carbonyl)-amino]-3,3-diphenyl-propionylamino}-5-guanidino-pentanoic acid methyl ester;
6-Amino-2-[2-[(biphenyl-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester;
6-Amino-2-[2-(2-benzenesulfonylamino-2-methyl-propionylamino)-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester; and
6-Amino-2-[2-[(biphenyl-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester.
Additional compounds of the invention include:
2-{3-(3-Fluoro-phenyl)-2-[2-(toluene-4-sulfonylamino)-acetylamino]-propionylaminol}-5-guanidino-pentanoic acid tert-butyl ester;
2-{3-(4-Fluoro-phenyl)-2-[2-(toluene-4-sulfonylamino)-acetylamino]-propionylaminol}-5-guanidino-pentanoic acid methyl ester;
2-{3-(3-Fluoro-phenyl)-2-[2-(toluene-4-sulfonylamino)-2-methylpropionylamino]-propionylamino}-5-guanidino-pentanoic acid methyl ester;
6-Amino-2-[2-[(biphenyl-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester;
6-Amino-2-[2-[(biphenyl-4-carbonyl)-amino]-2-methyl-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester;
N-(3-aminomethyl-cyclohexylmethyl)-3-(1H-indol-3-yl)-2-(2-benzenesulfonylamino-2-methyl-propionylamino)-propionamide; and
N-(4-aminomethyl-pyrid-2-ylmethyl)-3-(1H-indol-3-yl)-2-[(biphenyl-4-carbonyl)-amino]-propionamide.
In further compounds of the invention, R1 or R1xe2x80x2 is (C1-C8)alkyl- or phenyl(CH2)xe2x80x94 and said alkyl or phenyl group is optionally substituted by one or more halo or trifluoro(C1-C8)alkyl groups.
In further compounds of the invention, R2 is (C1-C8)alkyl-, optionally substituted by one or more halo or trifluoroalkyl groups, most preferably (C1-C3)alkyl-, optionally substituted by one or more halo or trifluoro(C1-C8)alkyl groups.
In further compounds of the invention, one or more of R3, R4, R5, and R6 is (C1-C8)alkyl- or phenyl(CH2)xe2x80x94, and said alkyl or phenyl group is optionally substituted by one or more halo or trifluoro(C1-C8)alkyl groups.
In further compounds of the invention, one or more of R7, R8, and R9 is (C1-C8)alkyl- or phenyl(CH2)xe2x80x94, and said alkyl or phenyl group is optionally substituted by one or more halo or trifluoro(C1-C8)alkyl groups.
In further compounds of the invention, one or more of R10, R11, R11xe2x80x2, R12 and R12 is (C1-C8)alkyl- or phenyl(CH2)xe2x80x94, and said alkyl or phenyl group is optionally substituted by one or more halo or trifluoro(C1-C8)alkyl groups.
With respect to trifluoro(C1-C8)alkyl substituent groups, all as aforementioned, the prefered group is trifluoromethyl.
The compound of formula (I) may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers, tautomers and stereoisomers of the compounds of formula (I), and mixtures thereof, although as will be described below in greater detail, certain isomeric structures are preferred.
The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula (I). The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1xe2x80x2-methylene-bis-(2-hydroxy-3-naphthoate)]salts.
With respect to the relatively limited number of compounds that so permit, the invention also relates to base addition salts of formula (I). The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g, calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
The subject invention also includes isotopically-labelled compounds, which are identical to those recited in Formula (I), but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of Formula (I) of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
The present invention also relates to a pharmaceutical composition for increasing growth hormone secretion in a mammal, including a human, comprising an effective amount of a compound according to formula 1, and a pharmaceutical carrier. The present invention also relates to a pharmaceutical composition for increasing gastrin secretion or glucagon secretion in a mammal, comprising an effective amount of a compound according to formula 1, and a pharmaceutical carrier.
The present invention also relates to a pharmaceutical composition for the treatment of diseases characterized by decreased levels of growth hormone, glucagon, or gastrin in a mammal, including a human, comprising an amount of a compound of formula (I) effective in such treatments and a pharmaceutically acceptable carrier. The present invention also relates to a pharmaceutical composition for the treatment of diseases in a mammal, including a human, wherein treatment can be effected by inhibiting the binding of somatostatin to the sst2-type receptor therefor, comprising an effective amount of a compound according to formula 1, and a pharmaceutical carrier.
The present invention relates to a method for treating growth hormone deficiency in a mammal, including a human. The present invention also relates to elevating the level of growth hormone in a mammal, including a human, wherein this is beneficial to the mammal nothwithstanding that the natural levels of growth hormone present in the mammal are within the normal range. In the practice of said method, there is administered a phamaceutical composition of the invention comprising a compound according to formula (1), and a pharmceutical carrier.
Similarly, the methods of the invention provide for increasing gastrin secretion or glucagon secretion in a mammmal, including a human, where this is medically appropriate. For example, gastrin is involved in protection of gastric mucosa against damage by chemical substances, e.g. alcohol (S. J. Konturek et al., European Journal of Pharmacology, 278(3), pp. 203-212, 1995). Glucagon is a counter-regulatory hormone that is used to treat hypoglycemia, and causes positive inotropic and chronotropic effects without the need for beta-1 adrenoceptor stimulation. It also can be used to correct beta-blocker, verapamil and imipramine overdose, and is used as adjunctive therapy in shock situations, for heart failure, and in treating postcountershock asystole (see C. M. White, Journal of Clinical Pharmacology,. 39(5), pp. 442-447, 1999)
In preferred examples of the invention, there are provided methods for treating a human for one or more symptoms of insufficient growth hormone secretion, or one or more conditions that may occur therewith and be exacerbated thereby, wherein said condition is selected from frailty, hypoglycemia, wrinkled skin, slow skeletal growth, reduced immune function, reduced organ functon, fertility disorders, bone disease, AIDS-related complex, cachexia, cardiac failure, ischemic heart disease, colon disease, metabolic disorders, renal failure, muscular dystrophy, and Turners syndrome, comprising administering an effective amount of a pharmaceutical composition as aforementioned.
In a further preferred example of the invention, there is provided a method for treating a non-human mammal to enhance the growth and performance thereof, comprising administering an effective amount of a pharmaceutical composition as aforementioned. Enhancement of growth and performance includes, for example, increased feed efficiency, improved milk yield or fertility, and increased leanness.
A highly preferred example of the invention provides a method whereinby secretion of growth hormone, gastrin, or glucagon can be increased on a sustained basis in a mammal, including a human, in need thereof, comprising adminstering a dose of a pharmaceutical composition as aforementioned. According to this example of the invention, physiologically adverse consequences of artificial fluctuations in the circulating (or locally needed) concentrations of these hormones can be avoided.
Although the pharmaceutical compositions and methods of the invention are described primarily in terms of use with humans, and non-human mammals, the skilled practitioner will immediately appreciate that the invention, in many of its aspects, may be usefully practiced with respect to birds, such as chickens and turkeys, and also fishes.
Definitions
In connection with the practice of the invention, the following definitions will generally apply.
The term xe2x80x9ctreatingxe2x80x9d, as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term xe2x80x9ctreatmentxe2x80x9d, as used herein, refers to the act of treating, as xe2x80x9ctreatingxe2x80x9d is defined immediately above.
The term xe2x80x9calkylxe2x80x9d, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof. Similarly, the terms xe2x80x9calkenylxe2x80x9d and xe2x80x9calknylxe2x80x9d define hydrocarbon radicals having straight, branched or cyclic moities wherein at least one double bond, or at least one triple bond, respectively, is present. Such definitions also apply when the alkyl, alkenyl or alkynyl group is present within another group, such as alkoxy or alkylamine.
The term xe2x80x9calkoxyxe2x80x9d, as used herein, includes O-alkyl groups wherein xe2x80x9calkylxe2x80x9d is as defined above.
The term xe2x80x9chaloxe2x80x9d, as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo.
An xe2x80x9carylxe2x80x9d group as used herein, unless otherwise indicated, includes an organic radical derived from a monocyclic or bicylic (C6-C10) aromatic hydrocarbon compound by removal of a hydrogen radical from a ring carbon of the aryl compound. An aryl group is optionally substituted by one or more substituents wherein, unless otherwise indicated, selection of each optional substituent is independent of selection of any other optional substituents, and perferably the number of optional substituents is between 0 and 3, more preferably between 0 and 2. It will be appreciated that the preferred number of substituents is determined in part by facility of synthesis. Representative aryl groups are phenyl and naphthyl.
A xe2x80x9cheteroarylxe2x80x9d group as used herein, unless otherwise indicated, includes an organic radical derived from a monocyclic or bicyclic (C1-C9) aromatic heterocyclic compound by removal of a hydrogen radical from a ring atom of the heteroaryl compound, said ring atom being uncharged in said compound. A heteroaryl group is optionally substituted by one or more substituents wherein, unless otherwise indicated, selection of each optional substituent is independent of selection of any other optional substituents, and perferably the number of optional substituents is between 0 and 3, more preferably between 0 and 2. It will be appreciated that the preferred number of substituents is determined in part by facility of synthesis. Representative heteroaryl groups include furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyi, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5, 6, 7, 8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, and benzoxazinyl; and the like.
A xe2x80x9ccycloalkylxe2x80x9d group as used herein, unless otherwise indicated, includes an organic radical derived from a monocyclic (C3-C10)cycloalkyl compound, by removal of a hydrogen radical from a ring carbon of the cycloalkyl compound. A cycloalkyl group is optionally substituted by one or more substituents wherein, unless otherwise indicated, selection of each optional substituent is independent of selection of any other optional substituents, and perferably the number of optional substituents is between 0 and 3, more preferably between 0 and 2. It will be appreciated that the preferred number of substituents is determined in part by facility of synthesis. Representative cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,3-cyclobutadienyl, 1,3-cyclopentadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,4-cycloheptadienyl, 1,3,5-cycloheptatrienyl, bicyclo[3.2.1]octane, bicyclo [2.2.1] heptane, and the norborn-2-ene unsaturated form thereof.
A xe2x80x9cheterocycloalkylxe2x80x9d group as used herein, unless otherwise indicated, includes an organic radical derived from a monocyclic (C3-C10)heterocycloalkyl compound by removal of a hydrogen radical from a ring atom of the heterocycloalkyl compound, said ring atom being uncharged in said compound. (fix) A heterocycloalkyl group is optionally substituted by one or more substituents wherein, unless otherwise indicated, selection of each optional substituent is independent of selection of any other optional substituents, and perferably the number of optional substituents is between 0 and 3, more preferably between 0 and 2. It will be appreciated that the preferred number of substituents is determined in part by facility of synthesis. Representative heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, and chromanyl.
In connection with the terms xe2x80x9carylxe2x80x9d group, xe2x80x9cheteroarylxe2x80x9d group, xe2x80x9ccycloalkylxe2x80x9d group and xe2x80x9cheterocycloalkylxe2x80x9d group, as herein defined, the term xe2x80x9coptionally substitutedxe2x80x9d means that one or more chemically and pharmaceutically acceptable functional groups may be bonded thereto. Such a group contributes properties useful to production, storage, or use of the inventive compounds as pharmaceuticals, or at least does not substantially negate their pharmacological activity. Such suitable substituents may be determined by those skilled in the art. Illustrative examples of suitable substituents include, but are not limited to, hydroxy, halo, amino, trifluoromethyl, carboxy, (C1-C6)alkoxy-, (C1-C6)acyloxy-, (C1-C6)alkylamino-, ((C1-C6)alkyl)2amino-, (C1-C6)acylamino-, cyano, nitro, (C1-C6)alkyl-, (C2-C6)alkenyl-, (C2-C6)alkynyl-, (C1-C6)acylamino-, cyano(C1-C6)alkyl-, trifluoromethyl(C1-C6)alkyl-, nitro(C1-C6)alkyl-, (C1-C3)alkyl(difluoromethylene)(C1-C3)alkyl-, (C1-C6)acylamino(C1-C6)alkyl-, (C1-C6)alkoxy(C1-C6)acylamino-, amino(C1-C6)acyl-, amino(C1-C6)acyl(C1-C6)alkyl-, (C1-C6)alkylamino(C1-C6)acyl-, ((C1-C6)alkyl)2amino(C1-C6)acyl-, (C3-C10)cycloalkyl(C1-C6)alkyl-, (C1-C6)acyloxy(C1-C6)alkyl-, (C2-C6)alkoxy(C1-C6)alkyl-, piperazinyl(C1-C6)alkyl-, (C1-C6)acylamino(C1-C6)alkyl-, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl-, (C2-C9)heteroaryl(C1-C6)alkoxy(C1-C6)alkyl-, (C1-C6)alkylthio(C1-C6)alkyl-, (C6-C10)arylthio(C1-C6)alkyl-, (C1-C6)alkylsulfinyl(C1-C6)alkyl- (C6-C10)arylsulfinyl(C1-C6)alkyl-, (C1-C6)alkylsulfonyl(C1-C6)alkyl-, (C6-C10)arylsulfonyl(C1-C6)alkyl-, amino(C1-C6)alkyl-, (C1-C6)alkylamino(C1-C6)alkyl-, (C1-C6)alkyl(difluoromethylene)-, (C1-C3)alkyl(difluoromethylene)(C1-C3)alkyl-, (C1-C6)alkoxy(C1-C6)acyl-, (C1-C6)alkylamino(C1-C6)acyl-, ((C1-C6)alkyl)2amino(C1-C6)acyl-, (C6-C10)aryl-, (C5-C9)heteroaryl-, (C6-C10)aryl(C1-C6)alkyl-, (C2-C9)heteroayl(C1-C6)alkyl-, (C6-C10)aryl(C6-C10)aryl-, (C6-C10)aryl(C6-C10)aryl(C1-C6)alkyl- (C3-C10)cycloalkyl-, (C3-C6)cycloalkyl(C1-C6)alkyl-, (C3-C10)heterocycloalkyl-, (C3-C10)heterocycloalkyl(C1-C6)alkyl-, hydroxy(C2-C6)alkyl-, (C1-C6)acyloxy(C2-C6)alkyl-, (C1-C6)alkoxy(C2-C6)alkyl-, piperazinyl(C1-C6)alkyl-, (C1-C6)acylamino(C1-C6)alkyl-, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl-, (C2-C9)heteroaryl(C1-C6)alkoxy(C1-C6)alkyl-, (C1-C6)alkylthio(C1-C6)alkyl-, (C6-C10)arylthio(C1-C6)alkyl-, (C1-C6)alkylsulfinyl(C1-C6)alkyl-, (C6-C10)arylsulfinyl(C1-C6)alkyl-, (C1-C6)alkylsulfonyl(C1-C6)alkyl-, (C6-C10)arylsulfonyl(C1-C6)alkyl-, amino(C1-C6)alkyl-, (C1-C6)alkylamino(C1-C6)alkyl-, and ((C1-C6)alkyl)2amino(C1-C6)alkyl.
Further aspects of the invention are described in accord with the Detailed Description of the invention which follows directly.
According to the practice of the present invention, the secretion of growth hormone from cells (such as those of the anterior pituitary) is facilitated by inhibiting the somatostatin-induced (and G-protein coupled) mechanisms that naturally oppose both calcium ion and cyclic AMP-mediated signals that otherwise trigger fusion with the cell membrane of cytoplasmic granule structures that contain growth hormone, and the subsequent release (secretion) of GH.
The present invention provides an effective approach to the treatment of frailty in older persons, which may be caused, in whole or part, by insufficient levels of growth hormone (GH), or impairment of any of several downstream physiological effects normally associated with growth hormone secretion. It is generally recognized that GH is important to the maintenance of connective and muscle tissue in adults, and may help, to some extent, to increase muscle mass. Thus growth hormone may be used to assist elderly patients even when growth hormone levels per se are not the cause of, for example, weakness, or attrition of muscle and connective tissues. The practice of the invention benefits other patients, such as children, when it can be demonstrated that secretion of growth hormone is inadequate, but is subject to enhancement. Deficiency in GH secretion, or resultant GH activity, may arise in several ways. For example, the gene sequence that encodes GH may be expressed in the nucleus at subnormal levels, processing of resultant RNA transcript or nascent polypeptide may be defective, or fusion of cytoplasmic GH storage granules with the cell membrane (with resultant release of GH) may be defective. Additionally, the patient may possess an allele of the GH gene that encodes a mutant protein having less biological activity. Alternatively, there may be an underlying deficiency of GHRH, or a defect in the GHRH receptor, or defects in the the GHRP receptor or deficiency of its endogenous ligand, or in respective signalling mechanisms. Additionally, there may be an excess of somatostatin. In all such cases, the resultant physiological deficiency can be treated by administration of the pharmaceutical compounds of the invention.
In a further aspect of the invention, the performance and growth rate of non-human mammals, such as livestock, is enhanced by appropriate administration of the compounds disclosed herein. Additionally, companion animals, and particularly older companion animals also benefit upon administration of the present compounds.
Although the compounds of the present invention act to indirectly facilitate release of mature growth hormone from the cytoplasmic storage granules of cells, additional therapeutic substances are known that can directly enhance such secretion, and further, can indirectly enhance production of growth hormone by via enhanced expression of GH-encoding DNA in the cell nucleus. In this regard, both growth hormone releasing peptide (GHRP) and growth hormone releasing hormone (also known as growth hormone releasing factor, GHRH/GRF) which act to release GH from cytoplasmic storage granules have been mentioned. Since the release of GH from such granules has been implicated as a signal triggering production of additional GH protein in the cells, it is expected that GH levels may be properly maintained in patients using a xe2x80x9cpush-pullxe2x80x9d approach.
Accordingly, a further preferred example of the invention provides for the co-administration of the somatostain-antagonist compounds of the present invention and GHRP or GHRH, or other substances of like effects. Medical treatment with GHRP (or GHRH) alone is described in the following representative publications: M. Thorner et al., Journal Of Clinical Endocrinology And Metabolism, 81(3), pp. 1189-1196, 1996; S. G. Celia et al., Peptides, 16(1), pp. 81-86, 1995; M. A. Bach et al., Journal Of The American Geriatrics Society, 44(9), S10, 1996; and J. A. Aloi et al., Journal Of Clinical Endocrinology And Metabolism, 79(4), pp. 943-949, 1994.
Finally, since growth hormone is very labile, and its half-life in the body is very short, it is difficult to provide a safe dosing program for direct administration of growth hormone itself, which avoids wide swings in circulating levels of the hormone. Current sustained release technologies for direct administration of growth hormone can be improved upon. In this regard, the practice of the present invention is particularly valuable to the clinician, since by only indirectly raising GH levels, the hormone""s release profile remains, at least in part, under the control of the body""s own regulatory feedback systems, and fluctuations in the levels of circulating GH are damped over time.
In the preferred practice of the invention, compounds show selectivity for the sst2 receptor compared with other receptor subtypes, for example sstl, sst3, sst4 and sst5. This selectivity minimizes the chance that other molecular biological or biochemical pathways will be adversely affected while growth hormone secretion is being upregulated. Most preferably, the affinity of a compound for the sst2 type receptor should be at least about 10 times greater than for receptors of the other sst-subtypes.
It should be noted that the compounds of the invention may work by more than one mechanism, including those unrelated to interaction at an sst-type receptor, and the utility of the present compounds in the practice of the invention, including for use in treating other disease states not particularly mentioned herein, is not limited by any particular theory as desrcibed herein or by those theories that is generally recognized by those skilled in the art.
Additionally, the compounds of the present invention may interact beneficially with sst-type receptors other than sst2, and may provide therapeutic benefits by acting as somatostatin agonists, rather than antagonists, at sst2 or other sst-type receptors. Various types of somatostain agonists are well known in the art, and the capacity of a compound of the present invention to act as an agonist, an antagonist, or as either, depending on physiological circumstances, can be predicted from the assays which are known in the art and/or described below. For example, measurement of cyclic-AMP, growth hormone release, microphysiometry responses, cell proliferation or protein kinase activity can be measured in cultured pituitary cells, cell lines or other cells such as neuroblastoma cells that express somatostatin receptors, and cells transfected with recombinant somatostatin receptorsincluding transfected yeast cells. (Y. C. Patel et al., Biochemical and Biophysical Research Communications, 198(2), pp. 605-612, 1994; M. G. Cattaneo et al., FEBS Letters, 397(2-3), pp. 164-168, 1996; J. A. Koenig et al., British Journal of Pharmacology, 120(1), pp. 45-51, 1997; D. Djordjijevic et al., Endocrinology, 139(5), pp. 2272-2277, 1998; W. R. Baumbach et al., Molecular Pharmacology, 54(5), pp. 864-73, 1998.
Generally, somatostatin or agonists thereof demonstrate inhibitory activity, hence a stimulus is first applied (e.g. forskolin for cyclic-AMP) and the inhibitory effect of somatostatin observed. Antagonists reverse the inhibitory effects of somatostatin.
Somatostatin agonists are recognized as useful therapeutics in the treatment of diabetes, for example, see H. Grxc3x8nbxc3xa6ck et al., Prog. Basic Clin Pharmacol. (Basel), 10, pp. 103-128, 1996. Somatostatin agonists are also recognized (see WO 98/44922) as useful therapeutics in the treatment of, for example, diabetic retinopathy, acromegaly, rheumatoid arthritis, neuropathic and visceral pain, irritable bowel syndrome, Crohn""s disease, and are useful to inhibit cell proliferation associated with cancer, and to prevent restenosis following angioplasty.
Additionally, it has been determined that compounds having affinity for sst2 receptors also have affinity for receptors such as mcr4 and MCH. sst2 receptors and MCH receptors are also  greater than 50% homologous. Thus the compounds of the present invention may also be used to treat medical conditions mediated through such other receptors.
As aforementioned. the compounds of this invention include all conformational isomers (e.g., cis and trans isomers, whether or not involving double bonds), tautomers, and all optical isomers of compounds of the formula I (e.g., enantiomers and diastereomers), as well as racemic, diastereomeric and other mixtures of all such isomers. With respect to the design of the compounds of the invention, particular features involving conformational and optical isomerism are of note.
In the below structure of a compound of formula (I), it is preferred that the Z group thereof have the following stereospecificity
Thus, the Z group defines an L-amino acid, preferably selected from the group consisting of L-tryptophanyl, L-histidinyl, L-3-methylhistidinyl, L-phenylalaninyl-, L-diphenylalaninyl-, L-3-fluorophenylalaninyl-, L-2-fluorophenylalaninyl-, L-4-fluorophenylalaninyl-, and L-tyrosinyl-, and which is most preferably, L-tryptophanyl.
It is less preferred that group Z have the following stereospecificity
wherein the Z group defines a D-amino acid; however, in this case, use of D-tryptophanyl- is highly preferred.
In the below structural component of a compound of formula (I), it is preferred that the W group thereof have a stereospecificity at the indicated position (which corresponds to the xcex1-carbon of an amino acids), such that L-amino acids, or other structures having the same absolute stereospecificity, are defined.
In preferred examples, the W group defines an L-lysine group or a (C1-C8)alkyl ester thereof, or an L-arginine group or a (C1-C8)alkyl ester thereof, and in a highly preferred example there is defined a (C1-C8)alkyl ester of L-lysine. Additionally, the W group can define an L-diaminopimelic, L-canavanine, L-ornithine, L-2,4-diaminobutyric, L-5-hydroxylysine, L-epsilon-N-methyllysine, L-histidine, or L-3-methylhistidine group.
Additionally, L-lysine is preferably selected to provide the xe2x80x9cWxe2x80x9d component, when Trp derivatives (whether L or R) are used to provide the xe2x80x9cZxe2x80x9d component.
L-Arginine is preferably selected to provide the xe2x80x9cWxe2x80x9d component when Phe (or a derivative thereof such as 2-fluorophenylalaninyl-, 3-fluorophenylalaninyl-, 4-fluorophenylalaninyl- or diphenylalaninyl-) is used to provide the xe2x80x9cZxe2x80x9d component. In this case, the stereochemistry provided within Phe, or a derivative thereof, should correspond to that of L-amino acids, if possible.
Additionally, many of the groups of the present compounds may be optionally substituted. As aforementioned, such substituents contribute properties useful to production, storage, or use of the inventive compounds as pharmaceuticals, or at least does not substantially negate their pharmacological activity. It will be appreciated that selection of optional substituents is further guided by principles recognized in the art, and/or is capable of validation through the use of the assays described in the present specification.
The compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared, for example, by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
Those compounds of the present invention that are acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
In a preferred example of the invention, the compounds of the present invention may be formulated with additional pharmaceutically active substances that directly or indirectly facilitate production and storage in cells of additional growth hormone, or precursor polypeptides thereof, or release of GH. Such additional substances include growth hormone releasing peptide (GHRP), growth hormone releasing hormone (GHRH), pituitary adenylate cyclase activating polypeptide (PACAP), dopaminergic agonists (e.g. bromocriptine), beta-adrenergic agonists (e.g. isoproterenol) and alpha 1-adrenergic agonists (e.g. methoxamine). For background information see E. O Soyoola et al., Proceedings of the Society for Experimental Biology and Medicine, 207(1), pp. 26-33, 1994; V. Locatelli et al., Pediatric Research, 36(2), pp. 169-74, 1994; and B. Velkeniers et al., Journal of Endocrinology, 143(1), pp. 1-11, 1994.
Equivalently, the additional pharmaceutically active substances may be provided as a separate formulation which is co-administered, or administered at some other timepoint(s) in the course of treatment.
This invention also encompasses pharmaceutical compositions containing prodrugs of compounds of the formula I. This invention also encompasses methods of treating or preventing disorders that can be treated or prevented by decreasing the levels of somatostatin comprising administering prodrugs of compounds of the formula I. Compounds of formula I having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain.
One of ordinary skill in the art will also appreciate that when using the compounds of the invention in the treatment of a specific disease, that the compounds of the invention may be combined with various existing therapeutic agents used for that disease, or for other metabolically related or unrelated disease states that may occur simultaneously. As aforementioned, the additional pharmaceutically active substances may be provided as a separate formulation which is co-administered, or administered at some other timepoint(s) in the course of treatment.
The compounds of the invention can also be used in combination with existing therapeutic agents such as the above mentioned growth hormone secretagogues for the treatment of growth hormone deficiency.
For the treatment of growth hormone deficiency, the compounds of the invention may be combined with agents such as recombinant growth hormone which is marketed by Genentech and licensees (Neutropin, Genotropin and Protropin), Bio-Technology General and licensees (Zomacton, Growject, Elvetium and SciTropin), Novo Nordisk (Norditropin), LG Chem (Eutropin), Ares Serono (Saizen and Serostim), Eli Lilly Co (Humatrope), Monsanto (Posilac brand of bovine growth hormone) and Alpharma (Reporcin brand of swine growth hormone).
The compounds of the invention can also be used in combination with existing therapeutic agents such as Geref (sermorelin, GHRH) from Serono Laboratories Inc.
The compounds of the invention can also be used in combination with existing therapeutic agents such as anabolic steroids, e.g. androisoxazol androstanolone (DHT, dihydrotestosterone, Stanolone, Anabolex, Andractrim), bolandiol, bolasterone, bolazin, boldenone (Equipoise), calusterone, clostebol (chlortestosterone, Steranabol, Alfa Trofodermin, Dermanabol, Trofodermin, Trofoseptine), danazol (Cyclomen, Danocrine), dehydrochlormethyltestosterone (turinabol, Oral-turinabol), drostanolone (dromostanolone, Drolban, Masterid, Masteril, Masteron, Metormon, Premastril), estradiol, ethylestrenol, fluoxymesterone (Halotestin, Ora-Testryl, Android-F), formebolone, furazabol (Miotolon), mestanolone, mesterolone (Proviron, Pluriviron), methandienone (methandrostenolone, Metaboline), methandriol, methenolone (Primobolan), methyltestosterone (Methandren, Premarin with methyltestosterone, Android, Oreton, Testred, Methyltestosterone tabs, Geri-Bons, Geri-tabs, Dermonal), mibolerone (Cheque), nandrolone (Deca-Durabolin, Durabolin, Nandrabolin, Anabolin, Androlone, Hybolin, Nandrobolic), norclostebol, norethandrolone (Nilevar), oxabolone, oxandrolone (Anavar), oxymesterone (Oranabol), oxymetholone (Anapolon 50, Androyd, Anadrol, Anasteron, Dynasten, Oxitosona, Plenastril, Synasteron, Zenalosyn), penmesterol, prasterone, quinbolone, stanozolol (Winstrol, Winstrol-V, Stromba, Strombaject), stenbolone, testosterone (Malogen, Delatestryl, Malogen, Neo-pause, PMS-testosterone Enanthate, Andriol, Duogex, Neo-Pause, Climacteron, Orchisterone-P, Oreton, Anadiol, Anatest, Testos-100,Heifer-aid, Synovex-H), tibolone, trenbolone (Parabolan, Finaject) or zeranol.
The compounds of the invention can also be used in combination with existing therapeutic agents such as Somazon (mecasermin, recombinant insulin-like growth factor I) from Fujisawa.
For the treatment of older patients with osteoporosis, suitable agents to be used in combination with the compounds of the invention include standard non-steroidal anti-inflammatory agents (hereinafter NSAID""s) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as celecoxib and rofecoxib, analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc.
The compounds of the present invention may also be used in combination with osteoporosis agents such as lasofoxifene, raloxifene, droloxifene or fosomax and immunosuppressant agents such as FK-506 and rapamycin.
The compounds of the present invention may also be used in combination with immunostimulant agents for the treatment of reduced immune function.
The compounds of the present invention may also be used in combination with fertility agents such as human menopausal gonadotropin, chorionic gonadotropin, follicle stimulating hormone, nafarelin, triptorelin, cetrorelix, and ganirelix for the treatment of infertility.
The compounds of the present invention may also be used in combination with AIDS therapies for the treatment of AIDS-related complex.
The compounds of the present invention may also be used in combination with anti-tumor necrosis factor agents such as infliximab (TNF monoclonal antibody) or etanercept (soluble TNF receptor) for the treatment of cachexia.
The compounds of the present invention may also be used in combination with potassium channel blockers, beta-blockers, anticoagulants or vasodilators for the treatment of heart disease.
The compounds of the present invention may also be used in combination with angiotensin II (ATII) antagonists or erythropoietin for the treatment of renal failure.
For administration to livestock, the compounds of the invention may also be used in combination with feed additives such as antibiotics (e.g. monensin, lasalocid, salinomycin, semduramicin, narasin, maduramicin, virginiamycin, polymixin, efrotomycin, avoparcin, lincomycin, bacitracin, bambermycins, novobiocin, erythromycin, oleandomycin, streptomycin, tylosin, penicillin, tetracycline, oxytetracycline, chlortetracycline, carbadox, olaquindox, neomycin moenomycin avilamycin and flavophospholipol), repartitioning agents, beta-agonists (e.g. Paylean, ractopamine, from Elanco), and also amiterol, bambuterol, bitolterol, broxaterol, buphenine, carbuterol, cimaterol, clenbuterol, clorprenaline, colterol, denopamine, dioxethedrine, dioxifedrine, dobutamine, dopexamine, doxaminol, etanterol, fenoterol, flerobuterol, formoterol, hexoprenaline, ibuterol, imoxiterol, isoetarine, isoxsuprine, levisoprenaline, mabuterol, mesuprine, metaterol, methoxyphenamine, nardeterol, orciprenaline, picumeterol, pirbuterol, prenalterol, procaterol, protokylol, quinprenaline, rimiterol, ritodrine, salbutamol, salmeterol, terbutaline, tretoquinol, tulobuterol, xamoterol and zilpaterol.
The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation. The active compounds of the invention may also be formulated for sustained delivery.
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, chewable tablets, or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner, or blended with petfood or animal feed, or as a pre-mix for blending with animal feed.
The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human is 0.1 to 100 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
Aerosol formulations for treatment of the conditions referred to above in the average adult human are preferably arranged so that each metered dose or xe2x80x9cpuffxe2x80x9d of aerosol contains 20 xcexcg to 1000 xcexcg of the compound of the invention. The overall daily dose with an aerosol will be within the range 0.1 mg to 100 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.
Injected doses are preferably administered from about once a month, up to about 1 to 4 times per day, at an individual dosing of 0.01-1 mg/kg (of active ingredient) and may be intramuscular, intravenous, or subcutaneous, for example.
As is well recognized, the precise dose, and method and timing of administration thereof, are capable of determination by those skilled in the art, and depend upon numerous factors including the activity of the therapeutic compound, the properties of the formulation thereof, the nature and location of the target tissue, and the particulars of the disease state as it exists in a particular patient. Additionally, when the compounds of the present invention are administered to a patient with additional pharmaceutically active substances, one or more pharmaceutical compositions may be used to deliver all of the active agents, which may be administered together, or at different times, as determined by those skilled in the pharmaceutical or medical arts.
The following reaction schemes illustrate preparation of compounds of the present invention. It will be appreciated that the groups represented by letters (xe2x80x9cRxe2x80x9d groups, and the like) in the Schemes do not always correspond with similarly defined component groups of the formula (I) compounds themselves, since certain functionalities of the reactants are modified when the products are formed. Thus, to facilitate presentation of the schemes, R1 and R1xe2x80x2, as referred to below, correspond to R1 and R1xe2x80x2 as used throughout the Specification in defining the compounds of formula (I), whereas Ar1, Ar2, Ar3, and R2 represent structures that overlap with those as elsewhere defined, as is readily apparent upon inspection. For example, Ar1, Ar2, and Ar3 do not correspond to xe2x80x9cAxe2x80x9d, but rather represent any (C6-C10)aryl or (C1-C9)heteroaryl group as defined herein. R2 typicially represents an alkyl group, whether primary, secondary, or tertiary, but can also be aryl or benzyl.
Generally speaking, the compounds of the present invention are made by a series of xe2x80x9ccondensationxe2x80x9d reactions in which certain reactive groups are appropriately protected, and the sequence of condensation is controlled. Schemes I and II demonstrate that the component materials may be coupled in more than one sequence. Referring to Scheme I, the compounds of formula 1 which include an L-arginine moiety, may be prepared from the compounds of formula 2 by removal of the guanidine-protecting nitro group via a reduction reaction using formic acid as reducing agent in the presence of palladium on carbon. In a typical procedure, the reaction mixture is stirred overnight under nitrogen, filtered, and the solvent then removed under reduced pressure. Recovered material may then be triturated with diethylether, and dried overnight under high vacuum to yield the final product. Although nitro is the preferred protecting group, Boc may also be used, in which case suitable reaction conditions for deprotection are stirring with trifluoracetic acid or hydrochloric acid.
Again referring to Scheme I, the compounds of formula 2 may be prepared by condensation of the compounds of formulas 3 and 4, for example in the presence of 1,3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride hydroxybenzotriazole and dimethylaminopyridine. The reaction mixture may then be washed successively with portions of 10% aqueous hydrochloric acid solution, followed by washes with 50% saturated sodium bicarbonate solution, and saturated brine. The resulting product 2 may then be dried over anhydrous magnesium sulfate, filtered, and the solvent removed under reduced pressure.
In a preferred example of the invention, compounds of formulas 3 and 4 include amino acid moieties which confer peptide-like structure on the final product compounds, consistent with their activity as somatostain analogs. Compound 3 may represent one of several suitably protected amino acids, for example, comprising a lysine, arginine, histidine, or ornithine residue, wherein the carboxyl group thereof is protected, for example, by a suitable alkyl group (R2). The stereospecificity at the subregion of the product compound defined as xe2x80x9cWxe2x80x9d herein is determined by the stereospecificity of the participating amino acid. In the practice of the invention, stereospecificity corresponding to an L-amino acid is preferred.
Note that L-lysine is preferably selected to provide the xe2x80x9cWxe2x80x9d component, when Trp derivatives (whether L or R) are used to provide the xe2x80x9cZxe2x80x9d component.
L-arginine is preferably selected to provide the xe2x80x9cWxe2x80x9d component when Phe (or derivatives thereof such as 3-fluorophenylalaninyl- or diphenylalaninyl-) is used to provide the xe2x80x9cZxe2x80x9d component. In this case, the stereochemistry provided within Phe, or a derrivative thereof, should correspond to that of L-amino acids, if possible.
The deprotection that occurs in step 2xe2x86x921 can be accomplished with a different agent, for example TFA, or depending on the amino acid moiety contributed by compound 3, a different deprotection strategy can be employed. For example in the case where the amino acid moiety is lysine, or a lysine-like structure, protection of the alkylamine side chain may be accomplished by providing compound 3 as a BOC derivative,
with subsequent coupling, followed by hydrolysis in HCl.
Compounds 4 are readily prepared from compounds 5 by hydrolysis under alkaline conditions, most preferably using LiOH in methanol/water.
Compounds 5 are prepared by reaction to form an amide linkage between compounds 6 and 7. It will be seen that compound 5 contributes the Z subregion of the final product 1, and is responsible for its stereospecificity. Although group Ar2 therein may be any (C6-C10)aryl group or (C1-C9)heteroaryl group as those terms are defined in the Specification, it is again preferred that Ar2 permit the Z subregion to contribute an amino acid moiety, for example, a tryptophanyl, histidinyl, phenylalaninyl or tyrosinyl group. In the practice of the invention, stereospecificity corresponding to an L-amino acid is preferred, although use of D-trypophanyl is also preferred.
Numerous recognized procedures can be used to react compounds 6 and 7 as herein required. For example, an alkyl ester of compound 6 can be reacted with a compound of formula 7 in triethylamine/methylene chloride with overnight stirring with a dehydrating agent such as dicyclohexylcarbodiimide, or more preferably, with hydroxybenzotriazole, 4-dimethylaminopyridine, and 1,3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride in methylene chloride. The solution may then be washed sequentially with sufficient portions of 10% hydrochloric acid, 50% saturated sodium bicarbonate, and saturated brine. The product may then be dried over anhydrous magnesium sulfate, filtered, and the solvent removed, for example.
It will be appreciated that groups R1, R1xe2x80x2 and Ar1 (and the reactants that provide them) are selected to permit all of the product compounds of the invention. In this regard, the following structures are representative of those that may be used in place of compound 7 in the practice of the invention, so the moieties [Axe2x80x94G] in the compounds of formula (I) are defined.
wherein Ar1 (or Ar3) is any (C6-C10)aryl or (C1-C9)heteroaryl group, and the synthesis of the resultant reactants will be apparent to those skilled in the art. For example, the above structures can be made from the corresponding amino acids.
As aforementioned, since the general reaction scheme herein involves a series of xe2x80x9ccondensationsxe2x80x9d, it will be appreciated that the illustrated reactions may be conducted in a different sequence, or equivalent reaction steps can be substituted. Scheme II is one such additional possibility, and illustrations of its use are found in the numbered Examples which follow.
Schemes III(a) and III(b) provide approaches to group xe2x80x9cWxe2x80x9d in the general structure Axe2x80x94Gxe2x80x94Zxe2x80x94W, where W is alternative (b)
wherein
Q is selected from the group consisting of (C6-C10)aryl, (C1-C9)heteroaryl, (C3-C10)cycloalkyl, and (C3-C10)heterocycloalkyl; and
R7, R8, and R9 are each independently selected from H, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted.
Schemes III(a) and III(b) outline representative syntheses of component W wherein each of R7, R8 and R9 is H, and Q is, for example, either cyclohexane or pyridine. Numerous equivalent schemes are available to the practitioner.
Referring first to Scheme I, product 14 of Scheme III(a), and similar compounds, can replace compounds of the formula 3, so that compound analogous to compounds 2 are prepared from compounds of formula 4. Compounds analogous to those of formula 1 are then prepared from compounds of analogous to those of formula 2 by removal of the protecting BOC group under acidic conditions.
Referring to Scheme III(a), compounds of formula 14 may be prepared from compounds of 15 by reduction with hydrogen under appropriate conditions. Compounds of formula 15 may be prepared from compounds of formula 16 via reaction using NaN3 to displace the mesylate ester of compounds 16. Compounds 16 may be prepared from compounds 17 with mesyl (methanesulfonyl) chloride under basic conditions, for example, in triethylamine/dichloromethane at 0xc2x0 C., in good yield. Compounds 17 may be prepared from compounds 18 by reduction at the carboxyl group thereof using BH3. Compounds 18, having the stereospecificity indicated in Scheme II(a), are prepared from racemic compounds 20 by chiral resolution with stereospecific xcex1-methylbenzylamine, followed by selective purification, such as by crystallization. Compounds 20 may be prepared from the corresponding aromatic compounds 21 by reduction with hydrogen, for example, under appropriate conditions. Compounds 21 in turn are prepared from the corresponding (unprotected) compounds 22 by reaction with BOC anhydride under standard conditions. Finally, compounds 22 may be prepared from available starting materials 23, by reduction of the cyano group with hydrogen over a Raney nickel preparation.
In Scheme III(b), advantage is taken of available starting materials to generate compounds of the formula 14xe2x80x2 in 2 steps, first from compounds of formula 24 using BOC anhydride. Compounds 24 are generated from compounds of formula 25 by reduction of both cyano groups, again with hydrogen and Raney nickel as catalyst.

Somatostatin antagonists and agonists that act at the SST subtype 2 receptor

Abstract: Compounds according formula (I)

Abstract: and pharmaceutically acceptable salts, solvates or hydrates thereof; wherein,

Abstract: G is selected from the group consisting of:

Abstract: xe2x80x83where X is CH2, SO2, or carbonyl; and R1 and R1xe2x80x2 are each independently selected from H, CN, (C1-C8)alkyl-, and phenyl(CH2)xe2x80x94, wherein said alkyl and phenyl groups are optionally substituted; and

Abstract: xe2x80x83where Z and W are as defined in the present Specificiation; and pharmaceutical compositions and methods useful to increase secretion of growth hormone(GH) from the anterior pituitary of mammals, including on a sustained release basis.